[1]SULKOWSKI MS, GARDINER DF, RODRIGUEZ-TORRES M, et al.Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection[J].New Engl J Med, 2014, 370 (3) :211-221.
|
[2]OMATA M, KANDA T, WEI L, et al.APASL consensus statements and recommendation on treatment of hepatitis C[J].Hepatol Int, 2016, 10 (5) :702-726.
|
[3]European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2015[J].J Hepatol, 2015, 63 (1) :199-236.
|
[4] European Association for the Study of the Liver.EASL recommendations on treatment of hepatitis C 2016[J].J Hepatol, 2017, 66 (1) :153-194.
|
[5]RAO HY, WEI L.EASL recommendations on treatment of hepatitis C 2015[J].J Clin Hepatol, 2015, 31 (7) :1008-1017. (in Chinese) 饶慧瑛, 魏来.2015年欧洲肝病学会丙型肝炎治疗推荐意见[J].临床肝胆病杂志, 2015, 31 (7) :1008-1017.
|
[6]AASLD/IDSA HCV Guideance Panel.Hepatitis C guidance:AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus[J].Hepatology, 2015, 62 (3) :932-954.
|